Home | News | Find a Doctor | Ask a Question | Free

What happened to the HairMagic trial?


What happened to this trial? Another hype?

GBIC Sets Firm Date for Start of Clinical Trial of Its Flagship Product, HairMagic 

Gulf Biomedical Corporation (OTC PK: GBIC) reports they have set Oct. 1 as the start date for the first clinical trial of its flagship product, HairMagic(TM). The trial will be conducted under the traditional scientific rules of a double blind study, and is intended to verify the successful results experienced in earlier anecdotal studies. 

The trial will involve 80 to 100 subjects and will be managed by a Houston medical clinic under the supervision of a Medical Doctor. Results should be available in early January, according to Gulf Biomedical President Don West. 

In the initial introduction of HairMagic, an all-natural, no-side-effects hair restoration product, 70 hair loss victims tried the product. All 70 reported success within the first few weeks of use. This is the anecdotal evidence which the trial is designed to verify. 

Meanwhile, Gulf Biomedical's planned product expansion continues. Two events signal progress toward the company's goal of putting a total of six herbal products on the market by the end of 2005. 

1. LoveMagic(TM), an all-natural, no-known-side-effects herbal supplement found useful in the treatment of erectile dysfunction is being readied for introduction this month. It will be the company's second entry into the multi-billion dollar nutriceutical field. 

2. MoodMagic(TM), an herbal formula developed by Gulf Medical herbalists to brighten the mood and fight depression in its users, is undergoing expert examination, with intent to introduce that product in September. 

3. Three additional herbal products are in the research phase and will address problems associated with excess weight, memory loss, and the retardation of aging. 

"Gulf Biomedical's mission," said West, "is to provide our customers with economical solutions to their everyday health and fitness problems without the serious side effects that go hand-in-hand with artificial pharmaceutical drugs." 

For more information please contact Investor Relations at (973) 351-3868 or visit www.hairmagicinfo.com. 

Disclaimer: This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of l995 relating to aspects of the Company's operations and strategies. Important factors could occur to cause actual results to differ materially from those described herein. There is a risk that the Company may incur losses. Readers are urged to consider these cautionary statements carefully. Forward-looking statements speak only as of the date of this news release, and the Company disclaims any obligations to update such statements.